AVALA RES
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Market Cap & Net Worth: AVALA RES (CVJ)
AVALA RES (F:CVJ) has a market capitalization of $326.08K (€317.67K) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #40682 globally and #6023 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AVALA RES's stock price €0.00 by its total outstanding shares 1588366665 (1.59 Billion).
AVALA RES Market Cap History: 2017 to 2026
AVALA RES's market capitalization history from 2017 to 2026. Data shows change from $3.00 Billion to $326.08K (-57.63% CAGR).
AVALA RES Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AVALA RES's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.48x
AVALA RES's market cap is 1.48 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $602.44 Million | $647.22K | -$16.94 Million | 930.81x | N/A |
| 2021 | $298.37 Million | $4.29 Million | -$25.10 Million | 69.50x | N/A |
| 2022 | $198.91 Million | $6.41 Million | -$26.47 Million | 31.03x | N/A |
| 2023 | $83.80 Million | $13.78 Million | -$33.79 Million | 6.08x | N/A |
| 2024 | $22.83 Million | $15.37 Million | -$51.24 Million | 1.48x | N/A |
Competitor Companies of CVJ by Market Capitalization
Companies near AVALA RES in the global market cap rankings as of March 18, 2026.
Key companies related to AVALA RES by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
AVALA RES Historical Marketcap From 2017 to 2026
Between 2017 and today, AVALA RES's market cap moved from $3.00 Billion to $ 326.08K, with a yearly change of -57.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €326.08K | 0.00% |
| 2025 | €326.08K | -98.57% |
| 2024 | €22.83 Million | -72.76% |
| 2023 | €83.80 Million | -57.87% |
| 2022 | €198.91 Million | -33.33% |
| 2021 | €298.37 Million | -50.47% |
| 2020 | €602.44 Million | -9.44% |
| 2019 | €665.21 Million | -67.87% |
| 2018 | €2.07 Billion | -31.02% |
| 2017 | €3.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of AVALA RES was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $326.08K USD |
| MoneyControl | $326.08K USD |
| MarketWatch | $326.08K USD |
| marketcap.company | $326.08K USD |
| Reuters | $326.08K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.